Noul, a South Korean artificial intelligence-powered diagnostics company, signed a supply agreement with an East African medical device distributor to provide its cervical cancer screening solution to Mauritius, according to company announcements. The deal marks Noul’s first commercial entry into the African diagnostics market.
Under the agreement, the East African distributor will manage local introduction and distribution of Noul’s products in Mauritius. The partnership aims to expand access to decentralized screening tools in regions where traditional laboratory infrastructure remains limited.
Technology Deployment in Mauritius
The deployment centers on Noul’s proprietary platform, branded as miLab, which automates diagnostic processes using AI microscopy. According to company technical specifications, the device integrates hardware, staining reagents, and artificial intelligence software to analyze microscopic slides without requiring external network connectivity or specialized pathology laboratories.
Cervical cancer remains a significant public health challenge in low- and middle-income countries due to the shortage of cytopathologists and centralized testing facilities. By automating the identification of abnormal cells on site, the platform aims to reduce turnaround times for patient results from weeks to minutes, enabling same-day treatment evaluations.
Commercial Strategy and Market Expansion
Noul representatives stated that the Mauritius agreement serves as a beachhead for broader expansion across the African continent. The company intends to use regulatory pathways established in Mauritius to pursue partnerships in neighboring East African nations and other regional health jurisdictions.
Medical device distribution in East Africa typically involves navigation of diverse national regulatory frameworks and procurement systems. By partnering with an established regional distributor, Noul plans to accelerate product registration and distribution logistics across local clinics and community health centers.
Global Health Impact and Validation
International health organizations increasingly emphasize decentralized diagnostics as a key strategy for meeting global elimination targets for cervical cancer. Automated microscopy solutions allow frontline healthcare workers to perform triage screening in primary care settings, bridging the gap between patient sampling and laboratory analysis.
Noul’s expansion into Africa follows previous deployment initiatives and pilot programs across parts of Asia. Company officials indicated that subsequent phases of the Mauritius project will involve clinical evaluations measuring diagnostic accuracy and workflow integration times within local public health facilities.
Related reading